Bank of Nova Scotia Cuts Holdings in Edwards Lifesciences Corporation $EW

Bank of Nova Scotia trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 13.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,854 shares of the medical research company’s stock after selling 12,818 shares during the quarter. Bank of Nova Scotia’s holdings in Edwards Lifesciences were worth $6,475,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Evermay Wealth Management LLC boosted its stake in Edwards Lifesciences by 4.0% during the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after buying an additional 128 shares during the last quarter. Rehmann Capital Advisory Group increased its stake in Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after acquiring an additional 130 shares during the last quarter. Florida Trust Wealth Management Co raised its holdings in shares of Edwards Lifesciences by 1.5% during the 4th quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after acquiring an additional 132 shares in the last quarter. McIlrath & Eck LLC raised its holdings in shares of Edwards Lifesciences by 14.6% during the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after acquiring an additional 135 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its position in shares of Edwards Lifesciences by 0.9% during the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after acquiring an additional 136 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 0.7%

EW opened at $83.21 on Tuesday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The stock’s fifty day moving average is $87.74 and its two-hundred day moving average is $83.86. The company has a market capitalization of $47.91 billion, a P/E ratio of 47.82, a PEG ratio of 2.07 and a beta of 0.86. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the prior year, the business earned $0.67 EPS. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,577 shares of company stock worth $3,855,527 over the last three months. 0.31% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on EW. Citigroup raised their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Barclays restated an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Robert W. Baird boosted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $99.55.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.